Module overview
Section 4 of 6 · Open sections

Required section · Section 4 of 6

Working the case

An outpatient specimen arrives for a bleeding-history workup. Collection is a clean 21-gauge venipuncture into a full 3.2% buffered citrate tube, gently inverted, transported at 20 C, and tested 95 minutes after collection. The specimen is not hemolyzed and not clotted, so it meets specimen acceptance for the declared PFA method before any result is interpreted.

The results: platelet count 238 x 10^9/L, within the 150 to 450 x 10^9/L interval. Hematocrit 40.8%, within the 35.0 to 50.0% interval. Collagen/epinephrine closure time 214 seconds, above the manufacturer's 3.2% citrate interval of 82 to 150 seconds. Collagen/ADP closure time 86 seconds, within the manufacturer's interval of 62 to 100 seconds. Medication history documents ibuprofen taken 8 hours before the draw.

Reasoning: this is a valid specimen for the declared PFA method, so the closure times can be interpreted rather than repeated for a collection problem. The normal platelet count and normal hematocrit remove two of the common non-specific explanations for a prolonged closure time, low count and low hematocrit, but removing those explanations does not prove a different one. An isolated prolonged collagen/epinephrine closure time with a collagen/ADP result inside the declared interval is a pattern compatible with an aspirin-like medication effect on this cartridge pair, and the documented ibuprofen exposure is consistent with that pattern.

What this result set does not do: it does not prove ibuprofen caused the prolongation, it does not rule out reduced VWF or an intrinsic platelet defect, and it does not stand in for a diagnosis. The correct next step is to release the method-specific result and comment according to local policy, and let qualified review decide whether medication washout and repeat testing, VWF studies, LTA, secretion testing, or flow cytometry is the appropriate next step. Labeling this result set an inherited platelet defect would overreach what a single PFA cartridge pair, on one draw, with a documented drug exposure, can support.

A compatible pattern documents what you observed and what does not exclude it; it is not the same statement as a cause.

Illustrative drawing — this picture was drawn rather than captured.

Workflow diagram of draw, tube fill, mix, and transport steps leading to a method-specific test window, with a box listing hemolysis, venous collapse, and microthrombi as rejection conditions.
Figure 1Preanalytical checkpoints from draw to the method-specific testing window.
Guided-case results for the bleeding-history workup.
ResultValueDeclared interval or flag
Platelet count238 x 10^9/L150-450 x 10^9/L
Hematocrit40.8%35.0-50.0%
PFA collagen/epinephrine closure time214 s82-150 s, manufacturer 3.2% citrate interval; high
PFA collagen/ADP closure time86 s62-100 s, manufacturer 3.2% citrate interval; within interval
Medication historyIbuprofen taken 8 hours before drawinterpretive flag

Knowledge checks

Reading and checks are open. Sign in only to save.

Knowledge check 1

In the guided case, collagen/epinephrine closure time is 214 seconds (above the 82-150 s interval) and collagen/ADP is 86 seconds (within the 62-100 s interval), with documented ibuprofen exposure. What is the most defensible interpretation to release?

Choose one option.

Section status

Finish this section

Reading and checks are open. Sign in only to save.

The module finishes after every required section is marked done and every check in those sections is correct.